Quince Therapeutics, Inc. Defined Contribution Plan, Cost
Quince Therapeutics, Inc. (QNCX) reported Defined Contribution Plan, Cost of $45.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-04-10
- Quince Therapeutics, Inc. defined contribution plan, cost for fiscal 2025 was $45.00K, a 55.00% decline from fiscal 2024.
- Quince Therapeutics, Inc. defined contribution plan, cost for fiscal 2024 was $100.00K, a 0.00% change from fiscal 2023.
- Quince Therapeutics, Inc. defined contribution plan, cost for fiscal 2023 was $100.00K.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2025-12-31 | $45.00K 10-K · filed 2026-04-10 |
| 2024-12-31 | $100.00K 10-K · filed 2026-04-10 |
| 2023-12-31 | $100.00K 10-K · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |